
Protagonist Therapeutics (PTGX) Stock Forecast & Price Target
Protagonist Therapeutics (PTGX) Analyst Ratings
Bulls say
Protagonist Therapeutics is poised for long-term success due to the positive data coming out of clinical trials and the strong partnerships with companies like Takeda and Johnson & Johnson. Their portfolio of peptide-based therapeutics targeting various diseases shows great potential and their financials are strengthened by recent milestone payments and opt-out fees. The successful launch and continued growth of Icotyde, as well as potential future approvals and partnerships, make Protagonist a strong investment opportunity.
Bears say
Protagonist Therapeutics is a clinical-stage biotechnology company that faces standard risks for this industry, including unexpected outcomes from clinical readouts, regulatory uncertainty, competition risks, commercial risks, manufacturing risks, and financial risks. Furthermore, unexpected safety concerns or unforeseen decisions from strategic partners, as well as increased regulatory, competitive, and pricing risks, could impact the company's rating and price target. Additionally, future cash needs and potential dilution risk are also concerns for this company.
This aggregate rating is based on analysts' research of Protagonist Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Protagonist Therapeutics (PTGX) Analyst Forecast & Price Prediction
Start investing in Protagonist Therapeutics (PTGX)
Order type
Buy in
Order amount
Est. shares
0 shares